1. Human Insulin from Recombinant DNA Technology
2. Development and Regulation of Biosimilars: Current Status and Future Challenges
3. Review, approval, and marketing of biosimilars in the United States;Aagaard AW;BioProcess Int,2010
4. EMA/CHMP/437/04 Rev 1.Guideline on Similar Biological Medicinal Products. Available at:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. April 2015. Accessed March 4 2015.
5. EMA/CHMP/BMWP/42832/2005.Guideline on Similar Biological Medicinal Products Containing Biotechnology‐Derived Proteins as Active Substance: Non‐Clinical and Clinical Issues. Available at:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf. June 2006. Accessed March 4 2015.